[
  {
    "question": "Patient with frequent falls and vertical gaze palsy Brain MRI showing? tectal atrophy",
    "option_a": "PSP",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder characterized by early falls, postural instability, and impaired vertical gaze. It falls under the umbrella of atypical parkinsonian syndromes. PSP is a tauopathy where abnormal tau protein accumulations lead to neurodegeneration, predominantly in the midbrain (including the tegmentum and dorsal aspects such as the tectal region), basal ganglia, and other subcortical structures. This degeneration disrupts normal ocular motor control and balance. Clinically, PSP presents with frequent falls, rigidity (especially axial), and vertical gaze palsy. The imaging findings typically include midbrain atrophy, sometimes emphasizing the dorsal region (tectum) which may be described as 'tectal atrophy.' The overall clinical presentation aligns with the expected pattern seen in PSP. The diagnosis of PSP is primarily clinical, supported by MRI findings such as midbrain atrophy with a reduced midbrain-to-pons ratio and the 'hummingbird' or 'penguin' sign on sagittal images. Differential diagnoses include Parkinson\u2019s disease, multiple system atrophy, and corticobasal degeneration. Detailed eye movement examinations and imaging are essential to distinguish these conditions. There is no definitive cure for PSP. Management is largely supportive and symptomatic, involving physical and occupational therapy, fall prevention strategies, and cautious use of dopaminergic therapy (which has limited benefit). For pregnant or lactating patients, supportive therapies remain the primary approach, with any pharmacologic interventions being used judiciously after assessing risks versus benefits. Option A (PSP) is correct because the combination of frequent falls, vertical gaze palsy, and MRI findings indicative of dorsal midbrain (tectal) atrophy is highly suggestive of PSP. Other options would typically display different imaging or clinical features. 1. Vertical gaze palsy is a hallmark of PSP. 2. Midbrain atrophy, particularly the 'hummingbird sign,' is a key imaging finding. 3. Early falls in an older patient should prompt evaluation for atypical parkinsonian syndromes like PSP. Recent updates emphasize early diagnosis of PSP using a combination of clinical criteria and imaging markers. Novel approaches focusing on tau-targeted therapies and improved supportive care protocols are currently under investigation.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "https://drive.google.com/file/d/1VfZYFbul4Bdva1QCy1T1IZikAjqDamLV/preview"
  },
  {
    "question": "Patient with Parkinson disease presented with peak dose dyskinesia",
    "option_a": "Amantadine.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Peak dose dyskinesia is a common complication in patients with Parkinson's disease who are on levodopa therapy. It manifests as involuntary, choreiform or dystonic movements when levodopa levels peak in the bloodstream. The phenomenon is thought to result from pulsatile dopaminergic stimulation leading to maladaptive plasticity in the basal ganglia. Amantadine, an NMDA receptor antagonist, can mitigate the effect of excessive glutamatergic activity that contributes to dyskinesia. Patients with Parkinson's disease may experience dyskinesias at the time of peak levodopa effect. These movements are often choreiform in nature and can interfere with daily activities. Diagnosis is clinical, based on the temporal relationship between levodopa dosing and the appearance of involuntary movements. Differential diagnoses include off-period dystonia and diphasic dyskinesia, which have distinct patterns in relation to levodopa plasma levels. Accurate symptom timing and careful patient history are key to differentiation. First-line management often entails adjusting the levodopa dosing schedule to smooth out serum levels. If dyskinesias persist, amantadine is recommended as a pharmacologic adjunct at doses typically starting around 100-200 mg/day. Second-line strategies can include modification of other dopaminergic medications. In pregnant or lactating women, the safety of amantadine (categorized as FDA category C) must be weighed against its benefits, and non-pharmacologic modifications may be prioritized. Option A (Amantadine) is correct because it has been shown to effectively reduce peak dose dyskinesia. Other options that might include mere dose adjustments or alternative agents may not have the same targeted efficacy against dyskinetic movements as amantadine in this scenario. 1. Peak dose dyskinesia correlates with the timing of levodopa peak plasma concentrations. 2. Amantadine is one of the few pharmacologic treatments that has evidence supporting its efficacy in reducing dyskinesias. 3. It is important to balance dyskinesia control with adequate management of Parkinsonian motor symptoms. Recent studies continue to support the use of amantadine for peak dose dyskinesia, and ongoing trials are investigating dose optimization and potential combination therapies to further reduce levodopa-induced complications.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with pic of PSP (impaired vertical gaze and axial rigidity) what is the dx",
    "option_a": "PSP",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder that is part of the atypical parkinsonian syndromes. It is most commonly recognized by its hallmark features of impaired vertical gaze, axial rigidity, and frequent falls. PSP is characterized by the abnormal accumulation of tau protein, a microtubule-associated protein, which leads to widespread neuronal degeneration. It particularly affects the brainstem regions, including the areas responsible for vertical gaze control such as the rostral interstitial nucleus of the medial longitudinal fasciculus, as well as basal ganglia and frontal lobe circuits that contribute to axial rigidity. Affected patients typically present with difficulty in moving the eyes vertically (especially downward), early postural instability, and an axial rigid posture. These clinical features, along with supportive imaging findings, help distinguish PSP from other parkinsonian disorders. The diagnosis of PSP is made clinically, with imaging studies such as MRI bolstering the diagnosis by revealing midbrain atrophy and the characteristic 'hummingbird sign.' Differential diagnoses include Parkinson\u2019s disease (which tends to have a stronger dopaminergic response and lacks the vertical gaze palsy), corticobasal degeneration, and multiple system atrophy. A thorough neurologic assessment with detailed eye movement evaluation is essential. Management is largely supportive since there is no cure for PSP. Treatment focuses on improving quality of life through physical therapy, occupational therapy, and speech therapy. Pharmacologically, attempts to use levodopa may yield limited benefit, and symptomatic treatments (such as for pseudobulbar affect) can be used. In pregnant or lactating patients, nonpharmacologic strategies should be prioritized, and any pharmacologic interventions should be selected with careful consideration of safety. Option A (PSP) is correct because the patient's presentation of impaired vertical gaze and axial rigidity, along with the imaging findings, align with a diagnosis of PSP. Alternative options would reflect different neurodegenerative disorders that do not fit the described clinical picture. 1. Vertical gaze palsy, especially a limitation in downward gaze, is a classic sign of PSP. 2. The 'hummingbird sign' on mid-sagittal MRI is highly suggestive of PSP. 3. PSP typically has a poor response to levodopa therapy compared to Parkinson's disease. Current research is focusing on tau-targeted therapies as potential disease-modifying treatments for PSP. In the meantime, early recognition and multidisciplinary supportive management remain the cornerstone of treatment.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of ataxia with one sister and brother but none of the parent involved (AR) with ataxia and decrease reflexes, and he closed his eyes and shake his head to change his gaze, normal musculoskeletal exam, and hypoalbuminemia and high cholesterol. What\u2019s the diagnosis?",
    "option_a": "Friedreich\u2019s ataxia",
    "option_b": "Ataxia oculomotor apraxia",
    "option_c": "Spinocerebellar ataxia III",
    "option_d": "Ataxia telangiectasia",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Movement Disorders",
    "explanation": "Ataxia with oculomotor apraxia (AOA) represents a group of autosomal recessive cerebellar ataxias that, in addition to incoordination, are characterized by impaired voluntary eye movements. This group includes disorders such as AOA1 and AOA2. The distinguishing laboratory findings \u2013 namely hypoalbuminemia and hypercholesterolemia \u2013 are most notably described in ataxia with oculomotor apraxia type 2. The underlying mechanism involves mutations in genes that are important for DNA repair and cellular homeostasis. In AOA2, for example, mutations in the SETX gene disrupt normal RNA processing and DNA repair. The metabolic derangements (low albumin, high cholesterol) are thought to reflect broader disturbances in hepatic or systemic metabolic processes tied to these genetic defects. Patients present with gait ataxia, dysmetria, and decreased deep tendon reflexes resulting from both cerebellar dysfunction and peripheral neuropathy. A notable feature is the impaired ability to initiate rapid eye movements (oculomotor apraxia), often compensated by head thrusts or turning, as described in the scenario. The absence of musculoskeletal abnormalities further supports a central neurologic cause rather than a primary muscular disorder. Key differentials include Friedreich\u2019s ataxia (which has a different profile with cardiomyopathy and diabetes, but without the hypoalbuminemia/hypercholesterolemia), ataxia telangiectasia (marked by telangiectasias and immunodeficiency), and autosomal dominant spinocerebellar ataxias (which usually do not exhibit these metabolic findings). Definitive diagnosis is supported by a combination of clinical features, laboratory findings, and subsequently confirmed with genetic testing. There is no disease\u2010modifying therapy available; management is supportive. Physical and occupational therapy are integral to maintaining mobility and function. Genetic counseling is recommended for family planning. Medications aimed at reducing symptoms (e.g., for neuropathic pain) may be used. In pregnancy or lactation, supportive measures are emphasized and medications, if necessary, are chosen based on safety profiles, often favoring non-pharmacologic management where possible. Option A (Friedreich\u2019s ataxia) is autosomal recessive but is typically associated with cardiomyopathy and diabetes and lacks the laboratory profile of hypoalbuminemia and hypercholesterolemia. Option B (Ataxia oculomotor apraxia) correctly encapsulates the clinical picture with oculomotor abnormalities, ataxia, and characteristic lab findings. Option C (Spinocerebellar ataxia III) is autosomal dominant and does not fit the familial pattern in this case. Option D (Ataxia telangiectasia) is accompanied by immunodeficiency and cutaneous telangiectasias, which are absent here. \u2022 Oculomotor apraxia is a key sign and often leads patients to compensate with head movements. \u2022 Laboratory findings such as low albumin and high cholesterol are clues to AOA2. \u2022 Genetic testing is essential for confirming the diagnosis in hereditary ataxias. Recent advances emphasize the use of comprehensive genetic panels to differentiate among the various ARCA. While treatment remains supportive, ongoing research into neuroprotective strategies and modulation of cellular metabolic pathways may offer future therapeutic avenues.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Young patient with dystonia and myoclonus\n- Diurnal variation",
    "option_a": "Myoclonic-dystonia DYT11 (SGCE gene), AD\nDystonia phenotypes with myoclonus\nTypical onset in childhood with dystonia in neck or upper limbs; myoclonus may predominate; caused by SGCE, KCTD17, and RELN.",
    "option_b": "Dopa-responsive dystonia (Segawa syndrome)\n- More common in females\n- Diurnal variation\n- Mild parkinsonism\n- Most common type >> AD, mutation in enzyme GTP cyclohydrolase I on chromosome 14 (DYT5)",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Myoclonus-dystonia (DYT11) is a movement disorder characterized by the presence of both myoclonic jerks and dystonic posturing. It typically presents in childhood or adolescence and follows an autosomal dominant inheritance pattern with maternal imprinting. Mutations in the SGCE gene (and in some cases other genes like KCTD17 and RELN) lead to dysfunction in the cerebellar\u2013basal ganglia circuitry, which mediates involuntary movement regulation. Although diurnal variation is a hallmark of dopa\u2010responsive dystonia (Segawa syndrome), the presence of prominent myoclonus points toward DYT11. Patients with myoclonus-dystonia present with action myoclonus typically involving the arms and sometimes the neck, alongside dystonic posturing. A classical feature is the improvement of symptoms with alcohol intake. While diurnal variation is strongly associated with dopa\u2010responsive dystonia, its presence in this scenario does not outweigh the significance of the combined myoclonus and dystonia seen in DYT11. Differentials include dopa-responsive dystonia (DRD), which usually lacks myoclonus and tends to present with lower limb dystonia and parkinsonian features. Other movement disorders such as juvenile parkinsonism or isolated dystonia are also considered. Genetic testing for SGCE mutations, in addition to a detailed family history, assists in clinching the diagnosis. First-line treatment often includes medications such as benzodiazepines or levetiracetam to manage myoclonus, and anticholinergics may be used for dystonia. Deep brain stimulation (DBS) is an option for refractory cases. In special populations such as pregnant or lactating women, the risks and benefits of antiepileptics and benzodiazepines must be evaluated, with a tendency to favor non-pharmacologic support and the use of agents with safer profiles where possible. Option A describes myoclonus-dystonia (DYT11) with its genetic background (SGCE gene) and clinical features (dystonia with myoclonus predominantly affecting the upper body), which is supported by the presence of myoclonus in the case. Option B outlines dopa-responsive dystonia (Segawa syndrome), which though noted for diurnal variation, is typically not associated with myoclonus. The absence of options C and D does not affect the decision-making, making Option A the best match. \u2022 Myoclonus-dystonia often improves transiently with alcohol ingestion. \u2022 Despite a hint of diurnal variation, the presence of myoclonus is what differentiates DYT11 from DRD. \u2022 Maternal imprinting may lead to an initially unremarkable family history even in autosomal dominant conditions. Recent studies have reinforced the role of the SGCE gene in myoclonus-dystonia. Moreover, evolving evidence on DBS and novel pharmacotherapies continues to refine the management of this disorder, while genetic counseling remains a cornerstone of comprehensive care.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "30-year-old male with hx of action tremor symmetrical and improve with alcohol 12 Hz frequency",
    "option_a": "Essential tremor",
    "option_b": "Enhanced physiological tremor",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Essential tremor is one of the most common movement disorders, characterized by a symmetric, action (postural or kinetic) tremor, most commonly affecting the upper limbs. It is often familial and considered to have a benign course. Although the precise etiology of essential tremor is not fully understood, current hypotheses favor abnormal oscillatory activity within the cerebellothalamocortical circuitry. GABAergic dysfunction has been implicated, suggesting a neurochemical basis for the tremor generation. Patients typically present with a high-frequency (usually 4-12 Hz) tremor that is most evident during voluntary movement and may sometimes affect the head or voice. A key clinical clue is the improvement of tremor with alcohol, which is highly characteristic of essential tremor and helps differentiate it from other tremor disorders. Differential diagnoses include enhanced physiological tremor (often stress or medication induced), drug-induced tremors, and other forms of movement disorders such as dystonic tremor. Evaluation includes a detailed clinical history, neurological examination, and sometimes tremor analysis with electromyography (EMG) to determine frequency and pattern. First-line management includes beta-blockers (such as propranolol) and primidone. In patients who do not respond or have contraindications, alternatives include topiramate and benzodiazepines. For refractory cases, surgical interventions such as deep brain stimulation (DBS) may be considered. In pregnancy, propranolol is used with caution due to potential fetal effects, and primidone is generally avoided because of its teratogenic risk. Non-pharmacological interventions like physical therapy can also provide symptomatic relief. Option A (Essential tremor) is the best match given the described symmetric action tremor that improves with alcohol and has a high frequency around 12 Hz. Option B (Enhanced physiological tremor) does not characteristically improve with alcohol and is usually transiently induced by stress, hyperthyroidism, or medications. The absence of further options (C and D) reinforces the choice of essential tremor. \u2022 Improvement with alcohol is a hallmark feature of essential tremor. \u2022 Essential tremor has a high familial prevalence and is usually an isolated finding on exam. \u2022 Differentiation from enhanced physiologic tremor is aided by the chronicity and responsiveness to specific medications. Recent guidelines support the use of propranolol or primidone as first-line therapies. Newer studies are exploring the efficacy of DBS and focused ultrasound interventions in refractory cases. Ongoing research into the genetic and neurophysiological basis of essential tremor may lead to more targeted therapies in the future.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Patient with PD hallucinations and memory problem what to give",
    "option_a": "clozapine",
    "option_b": "Quetiapine",
    "option_c": "Rivastigmine",
    "option_d": "Memantine",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson\u2019s disease (PD) can progress to involve not only motor symptoms but also neuropsychiatric manifestations such as hallucinations and cognitive impairment, leading to a clinical picture consistent with Parkinson\u2019s disease dementia (PDD). Cholinergic deficits are central to this condition, and cholinesterase inhibitors have been shown to improve cognitive symptoms and may have a beneficial effect on hallucinations. PD is characterized by degeneration of dopaminergic neurons in the substantia nigra; however, in PD dementia and associated psychosis, pathology extends to involve cortical and subcortical structures with significant cholinergic deficits and Lewy body deposition. These changes contribute to both memory impairment and visual hallucinations. Patients with PD dementia typically develop memory problems along with visual hallucinations after several years of motor symptoms. While psychosis can occur with PD medications, the presence of cognitive decline reinforces the diagnosis of PDD rather than isolated medication-induced psychosis. Evaluation includes a comprehensive neuropsychological assessment, careful review of medications, and ruling out other causes of delirium or primary psychotic disorders. Neuro-imaging may be used to exclude alternative diagnoses such as Alzheimer\u2019s disease or vascular dementia. A clinical history of longstanding PD supports a diagnosis of PDD. Rivastigmine, a cholinesterase inhibitor, is approved for the treatment of cognitive impairment in PD and has demonstrated beneficial effects on hallucinations. First-line management includes optimizing dopaminergic therapy while minimizing agents that may worsen psychosis. If hallucinations persist without significant cognitive decline, atypical antipsychotics like quetiapine or clozapine may be used with caution. In pregnancy and lactation, the use of cholinesterase inhibitors is generally avoided or used only when benefits outweigh risks; extensive counseling and alternative supportive measures should be considered. Option A (clozapine) can improve psychosis but carries risks like agranulocytosis and does not address memory deficits. Option B (quetiapine) is often used off-label for PD psychosis but also does not target cognitive impairment. Option C (rivastigmine) is approved for Parkinson\u2019s disease dementia and offers benefits for both memory and hallucinations, making it the optimal choice. Option D (memantine) has been studied in PD dementia but currently has less robust evidence of efficacy compared to rivastigmine. \u2022 Cholinesterase inhibitors, particularly rivastigmine, are first-line for managing cognitive impairment in PD. \u2022 Visual hallucinations in PD are often a manifestation of underlying cortical cholinergic deficits. \u2022 Caution and tailored dosing are essential when selecting therapies in PD due to the risk of worsening motor symptoms. Recent clinical trials and meta-analyses continue to support the use of rivastigmine in PD dementia. While atypical antipsychotics remain in use for isolated psychosis, emerging research is focused on targeting cholinergic deficits as a means to simultaneously address cognitive and psychotic symptoms in PD.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Bilateral UL dystonia in female improved with alcohol",
    "option_a": "(Clonazepam) is considered more useful for myoclonic disorders and is not the primary recommended agent for dystonia due to sedation risks and lesser efficacy as monotherapy. Option b (Depakine/Valproate) is primarily used for seizures or myoclonus, but not for isolated dystonia. Option c (Trihexyphenidyl) specifically addresses the cholinergic",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Movement Disorders",
    "explanation": "Dystonia is a movement disorder characterized by sustained or intermittent muscle contractions that cause abnormal, often twisting, postures and movements. It may affect a focal body region (e.g., upper limbs) and can sometimes demonstrate responsiveness to agents that modulate neurotransmitter balance. The condition is largely attributed to basal ganglia dysfunction with an imbalance between dopaminergic and cholinergic neurotransmission. The excessive cholinergic tone in the basal ganglia is implicated in dystonic symptoms. Alcohol may transiently improve symptoms by reducing cholinergic overactivity, thereby giving clues to therapeutic approaches. Patients with dystonia often present with involuntary muscle contractions that result in abnormal postures. The improvement with alcohol, though not a treatment, hints at the underlying neurotransmitter imbalance. In this case, bilateral upper limb involvement in a female is consistent with a focal or segmental dystonia, which is classically responsive to anticholinergics. Differential diagnoses include other movement disorders such as essential tremor (which also may improve with alcohol but is characterized predominantly by tremor), tardive dyskinesia, and even functional movement disorders. Careful clinical history and examination help differentiate these entities. First-line treatment for many dystonias involves anticholinergic agents, with trihexyphenidyl being a common initial choice. Other options include benzodiazepines (like clonazepam) as adjuncts if needed. In refractory cases, botulinum toxin injections may be used. In pregnant or lactating patients, the use of anticholinergics must be carefully considered; risks and benefits should be evaluated, and dosing should be minimized if treatment is necessary. Option a (Clonazepam) is considered more useful for myoclonic disorders and is not the primary recommended agent for dystonia due to sedation risks and lesser efficacy as monotherapy. Option b (Depakine/Valproate) is primarily used for seizures or myoclonus, but not for isolated dystonia. Option c (Trihexyphenidyl) specifically addresses the cholinergic-dopaminergic imbalance seen in dystonia, making it the correct choice. 1. Improvement of dystonic symptoms with alcohol suggests a cholinergic overactivity component. 2. Trihexyphenidyl is a cornerstone in the management of focal dystonias. 3. Awareness of medication side effects is important when treating movement disorders. Recent reviews continue to endorse anticholinergic therapy as a first-line option in dystonia management, with ongoing research focused on reducing side effects and improving efficacy. Neuroimaging and neurochemical studies have further supported the basal ganglia cholinergic-dopaminergic imbalance theory in dystonia.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Elderly man with DM, HTN, CABG & no Hx of stroke came with progressive dementia over 6 months, and falls, on exam he had Parkinson\u2019s signs in distal lower limb, limited vertical gaze, MRI showed ischemic changes. What\u2019s the diagnosis?",
    "option_a": "(PSP) is not supported by the presence of extensive ischemic changes and the patient\u2019s vascular risk factors; additionally, PSP usually shows midbrain atrophy rather than ischemic changes on MRI. Option b (Vascular Parkinsonism) is correct as it best fits the clinical picture given the patient\u2019s risk factors and MRI findings. Option c (DLB) is less likely because key features such as visual hallucinations and fluctuating cognition are not described. Option d (MSA) is unlikely due to the absence of autonomic dysfunction and cerebellar signs.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Movement Disorders",
    "explanation": "Vascular parkinsonism is a subtype of secondary parkinsonism resulting from cerebrovascular disease, often due to small vessel ischemic changes, and predominantly affects the lower limbs with associated gait disturbances and falls. Ischemic injury\u2014often secondary to microvascular infarcts\u2014affects the subcortical and basal ganglia regions, leading to impaired motor control. This results in parkinsonian features, particularly in the lower extremities, and contributes to a higher incidence of falls and gait instability. The presence of ischemic changes on MRI supports this mechanism. The patient\u2019s vascular risk factors (diabetes, hypertension, history of coronary artery bypass) predispose him to cerebrovascular disease. The relatively rapid progression of dementia over 6 months, lower limb parkinsonism, and frequent falls correlate with vascular parkinsonism. While limited vertical gaze is more classically associated with Progressive Supranuclear Palsy (PSP), in this context and given the MRI findings, it is more likely a nonspecific finding rather than true PSP. Main differentials include: Progressive Supranuclear Palsy (PSP), which typically presents with early falls and vertical gaze palsy along with midbrain atrophy on MRI; Dementia with Lewy Bodies (DLB), characterized by fluctuating cognition, visual hallucinations, and parkinsonism; and Multiple System Atrophy (MSA), which features autonomic dysfunction. The presence of vascular risk factors and ischemic MRI changes is key to identifying vascular parkinsonism. Management emphasizes strict control of vascular risk factors (hypertension, diabetes, and hyperlipidemia) to prevent further cerebrovascular damage. Rehabilitation, physiotherapy, and cautious use of dopaminergic medications (which often have limited effectiveness in vascular parkinsonism) are also recommended. In pregnancy and lactation (though these patients are typically elderly), any medication adjustments must consider maternal and fetal safety, with non-pharmacological strategies preferred when possible. Option a (PSP) is not supported by the presence of extensive ischemic changes and the patient\u2019s vascular risk factors; additionally, PSP usually shows midbrain atrophy rather than ischemic changes on MRI. Option b (Vascular Parkinsonism) is correct as it best fits the clinical picture given the patient\u2019s risk factors and MRI findings. Option c (DLB) is less likely because key features such as visual hallucinations and fluctuating cognition are not described. Option d (MSA) is unlikely due to the absence of autonomic dysfunction and cerebellar signs. 1. Lower body-predominant parkinsonism with gait instability is highly suggestive of vascular parkinsonism. 2. In patients with vascular risk factors, ischemic changes on MRI are an important clue. 3. Vertical gaze limitations can be seen in conditions other than classic PSP when ischemic lesions are present. Recent studies emphasize the role of small vessel disease in the development of vascular parkinsonism. Contemporary guidelines recommend aggressive management of cardiovascular risk factors and tailored rehabilitation strategies as the mainstay of treatment. Neuroimaging remains a critical tool for differentiating between vascular and neurodegenerative parkinsonian syndromes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Inclusion with alpha synucleinopathy contains:",
    "option_a": "(Ubiquitin) is present within Lewy bodies but is not the defining inclusion; option b (Lewy body) is correct as it is the hallmark inclusion in alpha",
    "option_b": "",
    "option_c": "(Amyloid) is specific to Alzheimer\u2019s disease; and option d (Neurofibrillary tangles) are also characteristic of Alzheimer\u2019s disease rather than alpha",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Movement Disorders",
    "explanation": "Alpha-synucleinopathies encompass a group of neurodegenerative disorders\u2014including Parkinson's disease and dementia with Lewy bodies\u2014characterized by the abnormal accumulation of alpha-synuclein protein within neurons. The aggregation of misfolded alpha-synuclein leads to the formation of Lewy bodies, which are intracellular inclusions. Although ubiquitin is often seen within these inclusions as a marker for protein degradation, the defining pathological feature is the Lewy body itself, which is primarily composed of aggregated alpha-synuclein. In Parkinson's disease and related disorders, Lewy bodies are typically found in the midbrain, particularly within the substantia nigra, and correlate with the clinical features of parkinsonism such as bradykinesia, rigidity, and tremor. Differentiating alpha-synucleinopathies from other neurodegenerative conditions involves identifying clinical features and, when available, pathological findings. For instance, Alzheimer's disease is characterized by extracellular beta-amyloid plaques and intracellular neurofibrillary tangles, rather than Lewy bodies. Management strategies in alpha-synucleinopathies focus on symptomatic treatments using dopaminergic therapies for motor symptoms and cholinesterase inhibitors for cognitive decline in dementia with Lewy bodies. While pathology-oriented therapies are under investigation, current management remains symptomatic. Pregnancy and lactation considerations are generally less applicable in these typically late-onset disorders, although dopaminergic therapies require individual risk-benefit assessments if used during pregnancy. Option a (Ubiquitin) is present within Lewy bodies but is not the defining inclusion; option b (Lewy body) is correct as it is the hallmark inclusion in alpha-synucleinopathies; option c (Amyloid) is specific to Alzheimer\u2019s disease; and option d (Neurofibrillary tangles) are also characteristic of Alzheimer\u2019s disease rather than alpha-synucleinopathies. 1. Lewy bodies are the key pathological inclusion in Parkinson\u2019s disease and dementia with Lewy bodies. 2. While other proteins like ubiquitin may be present, the aggregation of alpha-synuclein is central to disease pathology. 3. Differentiation from Alzheimer\u2019s disease is critical based on the type of protein deposition. Ongoing research is focused on understanding the mechanisms of alpha-synuclein misfolding and aggregation with the aim of developing disease-modifying therapies. Current neuropathological criteria continue to use Lewy bodies as the diagnostic hallmark in alpha-synucleinopathies.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "132- hallucination in PD on pramipexole\na) Add Rivastigmine  b) increase Levodopa  c) Stop pramipexole",
    "option_a": "(Add Rivastigmine) is more appropriate for cognitive symptoms or dementia associated with PD and is not the first step in managing acute drug",
    "option_b": "(Increase Levodopa) is contraindicated as it may further augment dopaminergic activity and worsen hallucinations. Option c (Stop pramipexole) directly addresses the cause by removing the dopamine agonist, making it the correct choice.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Movement Disorders",
    "explanation": "Hallucinations in Parkinson\u2019s disease (PD) are a recognized complication, often resulting from dopaminergic therapy. Dopamine agonists such as pramipexole can overstimulate dopaminergic receptors in the limbic system, leading to psychotic symptoms like visual hallucinations. Excessive dopaminergic stimulation, particularly via D3 receptors in the mesolimbic pathway, is implicated in the development of hallucinations. Pramipexole, a dopamine agonist, is known for its association with such side effects when administered in doses sufficient to impact limbic as well as motor pathways. Patients with PD on pramipexole who develop hallucinations are often experiencing medication-induced psychosis, which is an adverse effect directly related to dopaminergic overstimulation. Recognition of this side effect is crucial for appropriate management. The main differential considerations include PD dementia or comorbid psychiatric conditions. A thorough medication review is essential to distinguish drug-induced hallucinations from other causes. The absence of other psychotic symptoms and the temporal relationship with medication use are key diagnostic clues. The first-line management for hallucinations in PD involves reducing or discontinuing the offending agent\u2014in this case, pramipexole. If motor symptoms worsen or hallucinations persist, adjustments to levodopa therapy or cautious use of antipsychotics (e.g., low-dose quetiapine) may be considered. During pregnancy and lactation, careful evaluation is required because most antipsychotics and dopaminergic medications carry potential risks; ideally, medication adjustments should be minimized with a preference for non-pharmacologic interventions when possible. Option a (Add Rivastigmine) is more appropriate for cognitive symptoms or dementia associated with PD and is not the first step in managing acute drug-induced hallucinations. Option b (Increase Levodopa) is contraindicated as it may further augment dopaminergic activity and worsen hallucinations. Option c (Stop pramipexole) directly addresses the cause by removing the dopamine agonist, making it the correct choice. 1. Always review the PD patient\u2019s medication list when hallucinations occur, as they are often medication-induced. 2. Dopamine agonists, particularly pramipexole, are common culprits of hallucinations. 3. Reducing or discontinuing the offending agent is typically the most effective initial step. Recent guidelines emphasize the importance of medication review and adjustment in managing PD psychosis. Studies have shown that reducing dopamine agonist dosages can lead to significant improvement in hallucinations, and emerging research continues to explore safer therapeutic alternatives for managing PD motor symptoms while minimizing psychiatric adverse effects.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "131- asymmetrical tremors with rigidity",
    "option_a": "('Asymmetrical atrophy in MRI') is correct because it reflects the uneven neurodegeneration underlying asymmetrical tremors and rigidity in PD. Option b ('STN lesion') is incorrect as lesions in the subthalamic nucleus (STN) usually cause hyperkinetic movement disorders (e.g., hemiballismus) rather than the hypokinetic features seen in PD.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "Parkinson's disease (PD) is a progressive neurodegenerative disorder marked by cardinal motor signs such as resting tremor, rigidity, bradykinesia, and postural instability. A key early clinical feature is the asymmetry of motor symptoms, meaning that one side of the body is affected more than the other. PD results from the degeneration of dopaminergic neurons in the substantia nigra pars compacta. This leads to a decreased dopamine supply to the striatum and an imbalance in the direct and indirect pathways of the basal ganglia. The uneven loss of neurons can result in asymmetrical atrophy, which may be appreciated on advanced MRI imaging. This asymmetric atrophy mirrors the lateralized presentation of symptoms in early PD. Patients with PD initially present with unilateral or asymmetrical tremors and rigidity. As the disease progresses, bilateral symptoms typically emerge. The observed asymmetry on imaging supports the clinical diagnosis, even though PD is primarily a clinical diagnosis based on history and physical examination. Diagnosis is primarily clinical, based on criteria such as the UK Parkinson's Disease Society Brain Bank criteria. Differential diagnoses include atypical parkinsonism (e.g., progressive supranuclear palsy, multiple system atrophy), essential tremor, and vascular parkinsonism. Advanced imaging techniques like DAT-SPECT and MRI can help in atypical or unclear cases. Management is tailored to symptom control, primarily through dopaminergic therapy (e.g., levodopa/carbidopa, dopamine agonists, MAO-B inhibitors). In advanced cases, surgical options like deep brain stimulation may be considered. For pregnant or lactating women, the use of dopaminergic medications requires careful risk-benefit analysis and multidisciplinary management to minimize fetal exposure and ensure maternal health. Option a ('Asymmetrical atrophy in MRI') is correct because it reflects the uneven neurodegeneration underlying asymmetrical tremors and rigidity in PD. Option b ('STN lesion') is incorrect as lesions in the subthalamic nucleus (STN) usually cause hyperkinetic movement disorders (e.g., hemiballismus) rather than the hypokinetic features seen in PD. 1. Early Parkinson's disease commonly presents with unilateral or asymmetrical symptoms. 2. Imaging, while not first-line for PD diagnosis, can support the clinical picture in atypical presentations. Recent studies emphasize the role of imaging biomarkers like DAT-SPECT and advanced MRI in supporting PD diagnosis, particularly in cases where clinical findings are ambiguous, further underlining the asymmetric neurodegenerative process in PD.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "133- ttt of peak dose dyskinesia\na) Increase levodopa\u2019s dose  b) Amantadine  c) surgical",
    "option_a": "(Increase levodopa's dose) is incorrect because it may worsen dyskinesia by further increasing dopamine receptor stimulation. Option b (Amantadine) is the correct first",
    "option_b": "",
    "option_c": "(Surgical) is reserved for patients with refractory symptoms and is not appropriate as an initial treatment.",
    "option_d": "ue to its NMDA receptor antagonism and demonstrated efficacy in reducing peak",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Movement Disorders",
    "explanation": "Peak-dose dyskinesia is a common complication in Parkinson's disease treatment. It typically manifests as involuntary, hyperkinetic movements that arise when the plasma concentration of levodopa is at its peak. The dyskinesia is thought to result from pulsatile stimulation of dopamine receptors due to intermittent dosing. Over time, this leads to maladaptive changes in glutamatergic neurotransmission and synaptic plasticity within the basal ganglia. Drugs like amantadine work by antagonizing NMDA glutamate receptors, thereby reducing this excessive receptor stimulation and the resultant dyskinesias. Clinically, patients describe dyskinetic movements that coincide with the peak effects of levodopa. These movements can vary from choreic to dystonic and are typically most pronounced when the dopaminergic stimulation is highest. The diagnosis is based on the temporal relationship between medication dosing and the appearance of dyskinesias. Differential considerations include diphasic or off-dyskinesia, which differ by their timing relative to levodopa's effect. Detailed medication timing and patient history are key in differentiating these. First-line management for peak-dose dyskinesia involves adding amantadine to the treatment regimen, as it has been proven to reduce dyskinesia severity. Additional strategies include modifying the levodopa dosing regimen (e.g., dose reduction or fractionation) to minimize peaks. In refractory cases, surgical interventions like deep brain stimulation may be considered. Pregnant or lactating patients require special consideration; due to limited safety data on amantadine in these populations, treatment decisions must be individualized with multidisciplinary input. Option a (Increase levodopa's dose) is incorrect because it may worsen dyskinesia by further increasing dopamine receptor stimulation. Option b (Amantadine) is the correct first-line treatment option due to its NMDA receptor antagonism and demonstrated efficacy in reducing peak-dose dyskinesia. Option c (Surgical) is reserved for patients with refractory symptoms and is not appropriate as an initial treatment. 1. Peak-dose dyskinesia is directly linked to levodopa\u2019s peak plasma levels. 2. Amantadine is currently the best-supported pharmacologic option for managing peak-dose dyskinesia. Current guidelines and recent clinical trials reinforce the use of amantadine for peak-dose dyskinesia, with ongoing research into new formulations and adjunct therapies aiming to further minimize the impact of levodopa-induced complications.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "a) most likely due to stroke  b) symptomatic palatal myoclonus  c) Essential palatal myoclonus  d) FHX",
    "option_a": "('most likely due to stroke') merely states an etiologic factor without classifying the disorder correctly. Option b ('symptomatic palatal myoclonus') is the correct classification since it refers to palatal myoclonus secondary to identifiable lesions. Option c ('Essential palatal myoclonus') is incorrect for this scenario, and option d ('FHX') is not a recognized classification for this condition.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Movement Disorders",
    "explanation": "Palatal myoclonus is characterized by rhythmic, involuntary contractions of the palatal muscles. It can be classified into two types: symptomatic (secondary) and essential (idiopathic). Symptomatic palatal myoclonus is typically associated with lesions affecting the Guillain-Mollaret triangle (which includes the red nucleus, inferior olivary nucleus, and dentate nucleus). Such lesions, often due to stroke or tumors, lead to hypertrophic olivary degeneration, resulting in rhythmic contractions of the palate. Patients with symptomatic palatal myoclonus often have a clear history of a structural brain lesion (e.g., a stroke) and present with rhythmic palatal contractions. In contrast, essential palatal myoclonus lacks a demonstrable structural lesion on imaging. The diagnostic workup includes a detailed neurological examination and brain MRI to identify lesions in the Guillain-Mollaret triangle. Differential diagnoses involve essential palatal myoclonus, which is a diagnosis of exclusion when no structural abnormality is found. Management of symptomatic palatal myoclonus focuses on treating the underlying cause (e.g., post-stroke care) and symptomatic control of myoclonus through medications such as clonazepam, valproate, or other agents. For pregnant or lactating patients, choice of medication must weigh the potential teratogenic or neonatal effects, necessitating a careful, multidisciplinary risk-benefit assessment. Option a ('most likely due to stroke') merely states an etiologic factor without classifying the disorder correctly. Option b ('symptomatic palatal myoclonus') is the correct classification since it refers to palatal myoclonus secondary to identifiable lesions. Option c ('Essential palatal myoclonus') is incorrect for this scenario, and option d ('FHX') is not a recognized classification for this condition. 1. Symptomatic palatal myoclonus is most often associated with lesions in the Guillain-Mollaret triangle. 2. MRI is crucial in distinguishing symptomatic from essential palatal myoclonus. Recent advances in neuroimaging have enhanced the detection and localization of lesions within the Guillain-Mollaret triangle, thereby improving the diagnostic clarity for symptomatic palatal myoclonus. Treatment remains largely symptomatic, with a focus on underlying cause management where possible.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "case ataxia, slow saccades & optic atrophy",
    "option_a": "(SCA3) is incorrect because SCA3 usually lacks significant optic atrophy. Option b (SCA6) is not fitting because it generally presents with pure cerebellar ataxia. Option c (SCA7) is correct due to the hallmark combination of ataxia, slow saccades, and optic atrophy. Option d (DRPLA) is incorrect as its clinical presentation differs markedly from that of SCA7.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Movement Disorders",
    "explanation": "Spinocerebellar ataxias (SCAs) are a group of hereditary neurodegenerative disorders that predominantly cause cerebellar ataxia. Among these, SCA7 is distinct due to its association with visual impairment from optic atrophy. SCA7 is caused by a CAG trinucleotide repeat expansion in the ATXN7 gene, leading to the abnormal accumulation of ataxin-7 protein. This results in cerebellar degeneration, impaired ocular motor control (slow saccades), and retinal degeneration manifesting as optic atrophy. The combination of progressive ataxia, slow saccades, and optic atrophy is pathognomonic for SCA7. These symptoms reflect both cerebellar involvement and the specific retinal degeneration that distinguishes SCA7 from other SCAs. Diagnosis is confirmed with genetic testing for the ATXN7 mutation. Differential diagnoses include SCA3 (which often involves additional features such as extrapyramidal signs and peripheral neuropathy), SCA6 (typically presenting as a pure cerebellar ataxia), and dentatorubral-pallidoluysian atrophy (DRPLA), which has a different clinical spectrum including chorea and dementia. Management of SCA7 is primarily supportive and includes physical therapy, occupational therapy, and symptomatic treatments. There is currently no disease-modifying therapy. Genetic counseling is essential for affected families. In the context of pregnancy and lactation, management is supportive and genetic counseling is particularly important due to the risk of transmission; a multidisciplinary approach is required to manage potential maternal and fetal complications. Option a (SCA3) is incorrect because SCA3 usually lacks significant optic atrophy. Option b (SCA6) is not fitting because it generally presents with pure cerebellar ataxia. Option c (SCA7) is correct due to the hallmark combination of ataxia, slow saccades, and optic atrophy. Option d (DRPLA) is incorrect as its clinical presentation differs markedly from that of SCA7. 1. SCA7 is the only spinocerebellar ataxia typically associated with prominent retinal degeneration and optic atrophy. 2. Genetic testing is critical for definitive diagnosis and appropriate counseling in hereditary ataxias. Ongoing research continues to explore targeted therapies and gene-silencing techniques for polyglutamine disorders like SCA7. At present, management remains supportive, and current guidelines stress the importance of multidisciplinary care and genetic counseling.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "ALS-PD Guam",
    "option_a": "(tau) is correct because neuropathological studies of ALS",
    "option_b": "(amyloid) is incorrect since amyloid",
    "option_c": "(synucleinopathy) and Option D (Lewy body) are also incorrect because these pertain to alpha",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Movement Disorders",
    "explanation": "ALS-PD Guam (also known as the Guam parkinsonism-dementia complex) is a neurodegenerative disorder historically noted in the Chamorro population of Guam. The condition uniquely combines features of both amyotrophic lateral sclerosis and parkinsonism/dementia. A defining conceptual hallmark is its classification as a tauopathy \u2013 a disease driven by abnormal tau protein deposition. The pathological basis of ALS-PD Guam involves the accumulation of hyperphosphorylated tau protein, which aggregates into neurofibrillary tangles. These tau-positive inclusions disrupt normal neuronal function and are distinct from the amyloid-beta plaques seen in Alzheimer\u2019s disease or alpha-synuclein inclusions seen in Parkinson\u2019s disease and Lewy body dementia. Neuropathologic studies consistently demonstrate tau predominance in affected brain regions. Clinically, patients may exhibit symptoms of both motor neuron degeneration (ALS) and parkinsonian features such as rigidity and bradykinesia. This dual presentation correlates with the distribution of tau pathology that affects both the motor cortex and basal ganglia, explaining the mixed clinical features seen in affected individuals. Definitive diagnosis is based on neuropathological examination showing tau-immunoreactive neurofibrillary tangles. Differential diagnoses include Alzheimer\u2019s disease (characterized also by amyloid plaques and tau tangles), Parkinson\u2019s disease (with alpha-synuclein Lewy bodies), and other tauopathies like progressive supranuclear palsy. Clinical history and geographic/ethnic context, along with postmortem findings, are critical in differentiation. Currently, no disease\u2010modifying treatments exist for ALS-PD Guam. Management focuses on symptomatic relief and supportive care, including physical therapy and management of spasticity or rigidity. In pregnant or lactating patients, any symptomatic therapies (such as muscle relaxants or supportive medications) should be selected with careful review of the safety profiles and current guidelines. Multidisciplinary care is essential given the overlapping and progressive nature of the motor and cognitive deficits. Option A (tau) is correct because neuropathological studies of ALS-PD Guam consistently show hyperphosphorylated tau accumulation. Option B (amyloid) is incorrect since amyloid-beta plaques are not a significant feature. Option C (synucleinopathy) and Option D (Lewy body) are also incorrect because these pertain to alpha-synuclein pathologies seen in Parkinson\u2019s disease and Lewy body dementia, not in ALS-PD Guam. 1. ALS-PD Guam is a classic example of a tauopathy with overlapping features of ALS and parkinsonism. 2. Differentiation of neurodegenerative disorders often hinges on identifying the predominant pathological protein (tau vs. amyloid vs. alpha-synuclein). Recent research continues to explore the environmental and genetic factors contributing to tau hyperphosphorylation in Guam. Advances in tau imaging and biomarker studies may eventually lead to targeted therapies, although current management remains supportive.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Same above scenario (paroxysmal kinesigenic dyskinesia) and asked about the management.",
    "option_a": "Baclofen",
    "option_b": "Levodopa",
    "option_c": "Phenytoin",
    "option_d": "Tetrabenazine",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Movement Disorders",
    "explanation": "Paroxysmal kinesigenic dyskinesia (PKD) is a movement disorder characterized by brief, recurrent episodes of involuntary movements (dyskinesias) that are triggered by sudden voluntary movements. The underlying principle is abnormal neuronal excitability leading to transient dysregulated motor output. PKD is believed to be related to channelopathies and, in many cases, has been linked to mutations in the PRRT2 gene. These genetic changes affect synaptic transmission and neuronal excitability. The dyskinesias are thought to reflect an abnormal response of motor circuits to movement triggers, with sodium channel blockers modifying excitability. Clinically, PKD presents with very brief attacks of dystonia or choreoathetosis, triggered by sudden movement like turning or starting to run. The episodes are typically highly predictable. This clinical picture contrasts with other paroxysmal disorders that may be triggered by prolonged exercise or metabolic changes. Diagnosis is primarily clinical, relying on a detailed history of attack triggers, duration, and type of movement abnormality. Differential diagnoses include paroxysmal non-kinesigenic dyskinesia (which occurs without movement triggers) and paroxysmal exercise-induced dyskinesia (triggered by prolonged activity and generally lasting longer). Epileptic events must also be considered and ruled out. The first-line management for PKD typically involves sodium channel blockers. Although carbamazepine (and its derivative oxcarbazepine) is most commonly used, in the provided options carbamazepine is not listed. Phenytoin, another sodium channel blocker, has been documented as effective in some cases and therefore is an acceptable choice in this context. In pregnant or lactating patients, the choice of anticonvulsant requires careful consideration due to teratogenic risks (phenytoin is associated with fetal hydantoin syndrome), so alternative agents with a more favorable safety profile (or ensuring adequate folic acid supplementation) would be advisable. Option A (Baclofen) is a muscle relaxant and does not address the channelopathy in PKD. Option B (Levodopa) is used in dopa-responsive dystonia, not typically in PKD. Option C (Phenytoin) is correct in this context as a sodium channel blocker capable of suppressing the dyskinetic episodes. Option D (Tetrabenazine) is more commonly used in hyperkinetic movement disorders like Huntington\u2019s chorea and is not standard for PKD. 1. PKD episodes are typically very brief and almost always triggered by sudden movement. 2. While carbamazepine is the classic first-line treatment for PKD, phenytoin may be used effectively when carbamazepine is not an option. Recent studies have strengthened the association between mutations in the PRRT2 gene and PKD. Although carbamazepine remains the gold standard, research into alternative sodium channel blockers (including phenytoin) continues, with an emphasis on understanding individual variability in drug response and minimizing side effects, particularly in vulnerable populations like pregnant women.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "14-year-old lady medically free has episodes of jerky movements of the right upper limb followed by dystonia with posturing which happens suddenly when she turns while running, they also mentioned family history of migraine.",
    "option_a": "paroxysmal kinesigenic dyskinesia",
    "option_b": "paroxysmal exercise induced dyskinesia",
    "option_c": "DYT1",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "The clinical scenario describes a 14-year-old girl experiencing brief episodes of jerky movements and dystonic posturing of the upper limb triggered by sudden turning during running. This pattern is characteristic of paroxysmal kinesigenic dyskinesia (PKD), a primary movement disorder with episodic manifestations. PKD is often linked to mutations in the PRRT2 gene, which affects neuronal excitability and synaptic transmission. The abnormal response to voluntary movement results in transient hyperkinetic episodes. This channelopathy underlies the brief and predictable nature of the attacks. The sudden onset of symptoms with movement (specifically turning while running) is typical of PKD. The association with a family history of migraine provides an additional, though non-specific, clue as there is some familial clustering of paroxysmal disorders. The brief duration and predictable triggers help distinguish PKD from other dyskinesias. The diagnosis is clinical, based on attack characteristics and triggers. Differential diagnoses include paroxysmal exercise-induced dyskinesia (which is triggered by prolonged exercise and features longer episodes) and genetic dystonias like DYT1 (which typically present with more persistent dystonic features and have a different pattern of onset). A careful history and, when necessary, genetic testing (particularly for PRRT2 mutations) aid in differentiating these conditions. Management of PKD typically involves the use of sodium channel blockers such as carbamazepine or oxcarbazepine, which reduce the frequency and severity of episodes. Treatment is generally effective and well-tolerated. In pregnant or lactating patients, medication selection must balance efficacy with safety profiles; if using agents like carbamazepine, folic acid supplementation is recommended due to its teratogenic risk profile. Option A (paroxysmal kinesigenic dyskinesia) is correct given the triggering by sudden movement and the clinical presentation. Option B (paroxysmal exercise-induced dyskinesia) is incorrect because its episodes are usually triggered by prolonged exercise rather than abrupt movements. Option C (DYT1) refers to a specific genetic form of dystonia that typically presents with sustained dystonia rather than short, episodic attacks, making it less consistent with this case. 1. PKD attacks are brief and are reliably triggered by sudden movements, a key diagnostic clue. 2. A family history of migraine or paroxysmal disorders can be a helpful, though not definitive, indicator of PKD. Recent genetic studies have confirmed the role of PRRT2 mutations in many patients with PKD. Ongoing research is aimed at refining the diagnostic criteria and exploring tailored therapeutic approaches that optimize efficacy while minimizing side effects, especially in special populations such as adolescents and women of childbearing age.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Scenario of a patient with parkinsonian features and vertical gaze palsy",
    "option_a": "PSP",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "The scenario describes a patient with parkinsonian features coupled with vertical gaze palsy, a constellation of signs highly suggestive of Progressive Supranuclear Palsy (PSP). This condition is a recognized form of atypical parkinsonism with distinctive oculomotor abnormalities. PSP is a tauopathy characterized by the accumulation of abnormal tau protein in subcortical structures, particularly the brainstem and basal ganglia. The deposition of tau leads to neuronal dysfunction and degeneration in the midbrain, which in turn affects vertical gaze centers leading to supranuclear gaze palsy. Patients with PSP typically exhibit bradykinesia, rigidity, and postural instability similar to Parkinson\u2019s disease but are distinguished by early and prominent vertical gaze palsy, particularly difficulty with downward gaze. These features, along with early falls, help clinicians differentiate PSP from other forms of parkinsonism. Diagnosis of PSP is based on clinical criteria, including the presence of vertical gaze palsy and parkinsonian features. Neuroimaging, particularly MRI, may demonstrate the \u2018hummingbird\u2019 or 'penguin' sign due to midbrain atrophy. Differential diagnoses include Parkinson\u2019s disease (which lacks vertical gaze palsy), corticobasal degeneration, and multiple system atrophy. Management of PSP is primarily supportive as there are no disease-modifying treatments. Symptomatic treatment may include trial of levodopa for parkinsonian features, though the response is often limited. Physical therapy, occupational therapy, and speech therapy are critical in managing functional decline. In pregnant or lactating patients\u2014a rare scenario for PSP given its usual onset in older age\u2014medication use must consider fetal risk, and non-pharmacological interventions should be optimized. Option A (PSP) is correct because the combination of parkinsonian features and vertical gaze palsy is pathognomonic for Progressive Supranuclear Palsy. The other options (although not provided) would likely represent different atypical parkinsonian syndromes or misdiagnosed conditions, which do not present with the characteristic vertical gaze limitation seen in PSP. 1. Vertical gaze palsy, especially impaired downward gaze, is a hallmark sign of PSP. 2. MRI findings such as the \u2018hummingbird sign\u2019 can be highly supportive in making the diagnosis. Current research in PSP is focusing on tau-targeted therapies and novel biomarkers for earlier diagnosis. While symptomatic treatment remains the mainstay, clinical trials investigating tau aggregation inhibitors and other neuroprotective strategies are ongoing.",
    "exam_year": "2020",
    "exam_type": "Part I"
  },
  {
    "question": "Axial brain CT showing bilateral caudate atrophy and asked about the diagnosis",
    "option_a": "Huntington disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Movement Disorders",
    "explanation": "Huntington disease is an autosomal dominant neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the HTT gene. It is classically associated with chorea, cognitive decline, and psychiatric symptoms. On imaging, particularly axial brain CT, the hallmark finding is bilateral caudate atrophy with compensatory enlargement of the lateral ventricles. The mutant huntingtin protein leads to excitotoxicity, mitochondrial dysfunction, and ultimately apoptotic neuronal cell death, with the caudate nucleus and putamen being primarily affected. This pattern of neurodegeneration has been well demonstrated in both clinical and pathological studies. New research into gene silencing and neuroprotective strategies is ongoing. Patients typically present with involuntary movements (chorea), psychiatric disturbances (depression, irritability), and cognitive impairment. The imaging finding of caudate atrophy helps correlate the clinical picture with the underlying neurodegeneration seen in Huntington disease. Diagnosis is based on clinical history, family history, and characteristic imaging findings. Differential diagnoses may include other causes of chorea, such as Wilson\u2019s disease (which would have liver dysfunction and Kayser-Fleischer rings) or Sydenham chorea (usually self-limited and associated with rheumatic fever). Genetic testing confirms the diagnosis. While no cure exists, management is symptomatic. First-line treatments for chorea include dopamine-depleting agents like tetrabenazine or deutetrabenazine and antipsychotics if psychiatric symptoms are prominent. Supportive therapies (physical, occupational, and speech therapy) are essential. In pregnant or lactating patients, the risks and benefits of each medication must be weighed, and non-pharmacologic supportive care is particularly emphasized. Option A (Huntington disease) is correct because bilateral caudate atrophy on axial CT is the classic imaging hallmark for Huntington disease. There were no distractor options provided, so the marked answer appropriately identifies the diagnosis. 1. Bilateral caudate atrophy on imaging is a key diagnostic clue for Huntington disease. 2. The disease follows an autosomal dominant pattern, so family history is often positive. 3. Choreiform movements combined with cognitive/psychiatric changes should raise suspicion for this condition. Recent research has focused on gene silencing therapies and neuroprotective agents. Updated guidelines emphasize a multidisciplinary approach for symptomatic management and genetic counseling. While advances in symptomatic treatments are ongoing, the fundamental role of supportive care remains paramount.",
    "exam_year": "2020",
    "exam_type": "Part I",
    "image_url": "page_13.png"
  }
]